pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1185-1 |
Genomic Coordinates | chr14: 101042977 - 101043062 |
Synonyms | MIRN1185-1, hsa-mir-1185-1, MIR1185-1 |
Description | Homo sapiens miR-1185-1 stem-loop |
Comment | This sequence was proposed as a miRNA candidate by Berezikov et al by RAKE analysis . |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1185-1-3p | ||||||||||||||||||||||||||||||
Sequence | 53| AUAUACAGGGGGAGACUCUUAU |74 | ||||||||||||||||||||||||||||||
Evidence | Not_experimental | ||||||||||||||||||||||||||||||
Experiments | |||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ZFX | ||||||||||||||||||||
Synonyms | ZNF926 | ||||||||||||||||||||
Description | zinc finger protein, X-linked | ||||||||||||||||||||
Transcript | NM_001178095 | ||||||||||||||||||||
Other Transcripts | NM_001178085 , NM_001178086 , NM_001178084 , NM_003410 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ZFX | |||||||||||||||||||||
3'UTR of ZFX (miRNA target sites are highlighted) |
>ZFX|NM_001178095|3'UTR 1 TTATTGGCCCTGATGGACATCCTTTGACTGTCTATCCTTGCATGATTTGTGGGAAGAAGTTTAAGTCGAGAGGTTTTTTG 81 AAAAGGCACATGAAAAACCATCCCGAACACCTTGCCAAGAAGAAATACCGCTGTACTGACTGTGATTACACTACCAACAA 161 GAAGATAAGTTTACACAACCACCTGGAGAGCCACAAGCTGACCAGCAAGGCAGAGAAGGCCATTGAATGCGATGAGTGTG 241 GGAAGCATTTCTCTCATGCAGGGGCTTTGTTTACTCACAAAATGGTGCATAAGGAAAAAGGAGCCAACAAAATGCACAAG 321 TGTAAATTCTGTGAATACGAGACAGCTGAACAAGGGTTATTGAATCGCCACCTCTTGGCAGTCCACAGCAAGAACTTTCC 401 TCATATTTGTGTGGAGTGTGGTAAGGGTTTTCGTCACCCGTCAGAGCTCAAAAAGCACATGAGAATCCATACTGGGGAGA 481 AGCCGTACCAATGCCAGTACTGCGAATATAGGTCTGCAGACTCTTCTAACTTGAAAACGCATGTCAAAACTAAGCATAGT 561 AAAGAGATGCCATTCAAGTGTGACATTTGTCTTCTGACTTTCTCGGATACCAAAGAGGTGCAGCAACATGCTCTTATCCA 641 CCAAGAAAGCAAAACACACCAGTGTTTGCATTGCGACCACAAGAGTTCGAACTCAAGTGATTTGAAACGACACATAATTT 721 CAGTTCACACGAAAGACTACCCCCATAAGTGTGACATGTGTGATAAAGGCTTTCACAGGCCTTCAGAACTCAAGAAACAC 801 GTGGCTGCCCACAAGGGCAAAAAAATGCACCAGTGTAGACATTGTGACTTTAAGATTGCAGATCCATTTGTTCTAAGTCG 881 CCATATTCTCTCAGTTCACACAAAGGATCTTCCATTTAGGTGCAAGAGATGTAGAAAGGGATTTAGGCAACAGAGTGAGC 961 TTAAAAAGCATATGAAGACACACAGTGGCAGGAAAGTGTATCAGTGTGAGTACTGTGAGTATAGCACTACAGATGCCTCA 1041 GGCTTTAAACGGCACGTTATTTCCATTCACACGAAAGACTATCCTCACCGGTGTGAGTACTGCAAGAAAGGCTTCCGAAG 1121 ACCTTCAGAAAAGAACCAGCACATAATGCGACATCATAAAGAAGTTGGCCTGCCCTAACAATACTTCTACAGAACGTTTG 1201 TAGAGATATTGGCCTTGAAGCAGAAAATTCATTTTAAAGCCAATCAGTCTCATTCACATACAATACTGTATATTGATTTA 1281 TGCTGTGTACAAATAGAATTATTACTTCTAGTTGACTTTTTTTTAAATATACATTTTGCTCAGTAGTGTGTTCTGAATTC 1361 TATTCAGTTTGTTTAATAAATAGGGAAAACTGGCAACATGCTAGTTACTTTTAATAAAGTAATCCCTGATTCTATACCGA 1441 AGTTTTATATCTTAGAATTTTATATTTATTTAAATATTTACCTTGCTTACCTTGATGGTACTCTTCTAAGACCATTAACT 1521 TAAGGTAACTTTATATTGGTAACTCTGAAAGTATTCATGTTGACTCATTTTTTTCCCCATACATTTCTCACAATAAAATT 1601 GTCAGAGACATCTACTAATATAAATGGGAGATTTTACAGTCAGGTCTAATTATCATAACATGGAAGTCATTTACTTGTCT 1681 TGCTTAATATTTTCAGACCACTTGACAGTGAAAGTTTCCATTTGAGCTGTTGCGTCCCTGGCTTTGCTGAGTAAAGAGCA 1761 GTGGCTGGGTTCGTGTTTACTTTTCAAATATACTTCTTTTGGCTTTCTTTGGATTATTTACATCTTTTGTCAGCGTAGCA 1841 AACTTTTAGAAAACCTTATTGAAAAACTGTGCTTGCTCATGTTGTATTTTGATTATTCTGTCTGTGCGGCTTCATCTTGG 1921 AATGGTTGTGTGCTACAAATGACACTTACTGAGGACTGCATTTTGGAATCTCCTAGAGGTAACTCATGGCTTATAGGATC 2001 TTTTGCAACTTTATGTATGTAAATGTACCCTGAATTATATATATACACATATATATCATGTACCTGTGTGTATTGCTTAT 2081 TTTACATATTTATACACACAACCCCAAGTAGTAGTTGTTTAAAATCTATAATGAAAAGTATTAAATTTACAATAACATGA 2161 AAGATCCAGGGATGCATGAGAGAGCATTTTGTAAGTCATGCTCTTCAGAGAGACTACTCAGGTGAAGAATTAGAAGGAAA 2241 ATAAGGACACTAGTATTTTTAAAGAGTAAAGATATTTTCTTTTAAATATCTTTGGTAATTGAAACATAGAGGTTAAGATG 2321 TTTCTAGGTAGAATGTTTTCATACAATTTCACCTCCATGTCTTTATGTTTTTCTGAAAAGCAAATGAGTATCCAGACATG 2401 ACTCCCACAGTTCTCTTTGAGAAGCCTGAGAGGGAACTCTGTCTTACCTAGTGAGGGGGATGGAAAAGAAGTGATGGCTC 2481 TGTGGACCAGAGAACGGGTGCTAATTATGACTTCACACTCGGCAAGTTCAGGCTGATCTGTTATTTCTCAGTTACAGTTA 2561 GCAAACTTTAAAAACTTAACACTCAAGTTGGCTTTGATTAAAAGGTAAAGATGTGTTTTAAGTGGATAAGGAAAGTCTGA 2641 GGCCTTATTTGGAACATCACTAAGTCTTCCACAGGTTTTTTGTTTGTTTGTTTTTTTTTGTTGTTTTTTTTTCTTAAGAC 2721 GGAGTCTTGCTCTGTTGCCCAGGCTGGACTGCAGTGGTGTGATCACTGCAACCTCTGCAGCTCACTGCAACCTCTGCTTC 2801 CTGGGTTCAAGCAATTATCTGCCTCAGCCTCTCGAGTAGCTGGGATTACAGGCGCCCACCACCACGCCCGGCTAATTTTT 2881 TGTATTTTTAATAGAGATGGGGTTTCACCATCTTGGCCAGGCTGGTCTTGAACCCTGACCTCGTGATCCACCTGCCTCGG 2961 CCTTCCATAGTGCTGGGTTTACAGGCGTGAGCCACCGTGCCCAGACACCACATAGGTCTGAATCAGTGTCATACATTCAT 3041 AAAACAAACTCGGTTAATTAGAACTTGGTTATGTTAAGACGAATCTGGGAGAACAGAAAACAGTTTTTGGGGTCCCTTCA 3121 GTTGGCTATTGGTCCGTATGCATCTAGCACATTGTAGGAGATTTAGAAATTGTCTTCCCACCCGATAGCTGCCTTGTCAC 3201 CTCATTATGGTGCTCCATCCCCTGTGTGCTTAGGTTTTTACCTTTCATCTTTCTCTTTGCCATTGATGTTTGTATTCAAG 3281 AGTTATATTTTTAGGGTTAGAAATCAAAATATTTGGTGTTTGGCAAACCTCTGAAGTGCTAGACTGATTTAGTCTAGTTT 3361 TAAACCAAGTGCTTTAGGCAGGTGTGAACTCCAGCCCAAATGCCAGTCAAAGTCAAGGCATGGGTTTTCCTAGCCTATCT 3441 TATAGGAAATTCCTGTACCTTCTTGGCCCCCATAATGTGTTTTTTTTTTTTTTTTTTTTTTAAACTAACTTACAATTTTG 3521 TGATCCGTGATTCATTGCCCTGCGATTCTTGAAAGCTCTGTCTGTTTTTTTGTGAGAACCTTTAAAATCTCCCTTAATTT 3601 TTATTTTCCCAGAAATAATGTAAAAACACTTAAATGAAAGTGGAAATGTATTAATTTTAAATCCTATAAAATTAATACAG 3681 AAAATATAAATGATTGGGTCATTTAACTATATTTTTTTAAATAAACTGAAAGATAAAGAACACAACACTTCACACATTTT 3761 ATATTTCTCTTACATACTCCGGAATCATACACAGTTCTTTTTAAAGCACAACATTAAAACCTTTAAAAGGTATTTAAGGG 3841 TTTGGTCAAGTGAATATGATAAAACATACTTGTCTGTATAAAGAGAAAATGAAATTGTAGTCACTGTTATGTACTGACAT 3921 TAGTTACAACCTAGTTTTAATTCTTAAAACAATTTTGATTAGCAAAGCTAAAAAAAAATGGATGTTTCAGTTAAATGTTT 4001 TAAAGAGGTACAGATTTTTACAAGGACATAATATAAGTTATTGTTCTGTAGAAATATCCTATTAAATATTGTATGTCCCT 4081 CCCTCTGTACACTTTGTAAAGAAAGTAAAATACATAAAAAGAAAATCATATAGGGATGTGTGACATTATTGTAATTGTGT 4161 ACTTGAGAATAACGTGCAAAAATAAAAATCAGAATATTTTCCTGTTATTGAATGTTTAGTCTATTTGATACCAGTACTAA 4241 GTTAATGCTTTTTCTCAAGGAAAAAAAATGTACAGTTTTTGTAAACCTAATAAACATCAAAAGCAGTGGATTATTTTCAT 4321 CCCCCCATTTCTTAATTTCTTTTTCACAGCAGTGGAATGCAAAGTGCTTGATTGCTTTGAATTTTGTGACTCGGATGCAA 4401 ATACTGGTAATATTTCAGTTCTGTGAATTTGCAAGTAATATTTCAGAGAAGTTAAGAGGTGATTGGTGAGTCCTTTGATG 4481 AGCATGTCCTTGGAATTCATTTTTTCTTTTATCTTCATAAAGGATTTGTTTTATTAGCATCTCCAATTCCCCTGAGATAA 4561 ATTACTCATGCATAAAGTGGTTTTTGAGAGCACTTAAAGTTCATTTCAGTATTAATTTACAGCATATTTAATCAGTGGGG 4641 ACTGTTACCACCTCCACAACAGAAATCATGCCCTCGAGTTACCCCACTGCGCCCAGTTTAGAGGACTAGTAGATGCTAAC 4721 ATACTAGGGAATGGTCATTGCCACAGTTAAAAATCGGCAGTTAAGTAAATGTCAGGAGTCAAAAGAGATAGAGTTGTGCC 4801 ATCTTTGATTTTATAGACAAGATTCTGCAGTTCTTCCAACTGTATGAACAAACGTTTGCCTAATAGTTGAAACAATAAAT 4881 TAAAATTTTAGGTAAATGACGAAGGGAATGTGGTGAATGTCACTGTCCAGAGCCATAAATCAGACAAAACCATACATAGC 4961 ATGCTGAAAAACTTTTGTAATGGAACACCCAACAAATGACACCTAACCTGTCTGTGATCCAACAAGTCCGATAACATGCT 5041 GCTGTATTTGTATTCTCTGGGAATCTCAGTATTAATAATTTCATTTCCCACAAATTCTAGCATTCATGTAAGGAAAAACA 5121 TGGCTAATCAATATCTTAAAGGGGCAATCTTTCAGAGCAGTGGTTTTCAAAGTATGGCCGGACAGCATTGGCAGCATCTT 5201 AATCTCCTGGGACTTTGTTAAAAATGCAAATTCTCAGCCCCACCCTAGTCCTACTGAATTGGGAAACTGGCGTGGGACCC 5281 AGCAGTCTTTGTTTTAACATGTTCTCCAAGTGATTCTGATGCCTGTTCAAACTTGGGAAACACTTTTAGAGCACTTGAGG 5361 AACCTAAAAGATGACTGGTTCAGCATTTTGTGTGGTAGATAAGAAAGAAATTATCACAAAAAATCAGAAATGAACAGTGA 5441 GAGAAAAATAGGACCCCAGACAGTTTATACCTTCCATTTGCTGTTTTAAAAGTGTGAGCCTGCCAAGTCAACAAGTATGC 5521 CTTTAGCGCACATGTAAATAGCCTGCACTTCCTAAATCTCGTGTGGCCTCCCATGGTTACATTCTTCAAAGGTAAACTGA 5601 GTTGAGAGGAAGATTCAGCATTTAAAAGAGAAGGGTTGAAAAAGATTGTGTGTGTGTGTGTGTGTGTTTAATTGGCCCAG 5681 GGTTACTTAAATAAATCATAACCATTTTGCCACATTCTGTAACTGTTTAGCTAAGGTCAAATTAAGTTTACCCTATGGAT 5761 TTTGTTTCATCTTTTGTTTCGTGTATATACTGTTTGCCTTTTTCATAAAAATCTTGGATTTGTTATATATTGTTCCTGTT 5841 ATTTTTGACATCTTTGCTATTGTAAATAAATTACTATTTTGTTTTAAGTTACCCTAGTGGAGTGTTGGCTATAGACAAGG 5921 TATATACTCGAAACGAGGAGACTTAAATCACACAGTTAATGAATTCCCAACTTGTTTGAAGCTGGAGGTGATTCGACTCC 6001 CTTCAGTGGTTCAACACTAATAATAGCACCAAGGAACATGTCACTGGTGCATATAGG Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000539115.1 | 3UTR | CCAAUCAGUCUCAUUCACAUACAAUACUGUAUA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
114 hsa-miR-1185-1-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT066415 | TBK1 | TANK binding kinase 1 | 2 | 4 | ||||||||
MIRT073567 | NR2F2 | nuclear receptor subfamily 2 group F member 2 | 2 | 2 | ||||||||
MIRT074516 | USP1 | ubiquitin specific peptidase 1 | 2 | 4 | ||||||||
MIRT080576 | PMAIP1 | phorbol-12-myristate-13-acetate-induced protein 1 | 2 | 6 | ||||||||
MIRT086539 | HSPE1-MOB4 | HSPE1-MOB4 readthrough | 2 | 2 | ||||||||
MIRT086547 | MOB4 | MOB family member 4, phocein | 2 | 2 | ||||||||
MIRT088684 | EML4 | echinoderm microtubule associated protein like 4 | 2 | 4 | ||||||||
MIRT090811 | MBNL1 | muscleblind like splicing regulator 1 | 2 | 4 | ||||||||
MIRT095500 | PURA | purine rich element binding protein A | 2 | 2 | ||||||||
MIRT109530 | KLHL15 | kelch like family member 15 | 2 | 6 | ||||||||
MIRT109807 | ZFX | zinc finger protein, X-linked | 2 | 2 | ||||||||
MIRT117888 | ZBTB7A | zinc finger and BTB domain containing 7A | 2 | 2 | ||||||||
MIRT120273 | GSK3B | glycogen synthase kinase 3 beta | 2 | 4 | ||||||||
MIRT149892 | LDLR | low density lipoprotein receptor | 2 | 2 | ||||||||
MIRT178475 | LCOR | ligand dependent nuclear receptor corepressor | 2 | 4 | ||||||||
MIRT193445 | RORA | RAR related orphan receptor A | 2 | 2 | ||||||||
MIRT198527 | DSG2 | desmoglein 2 | 2 | 2 | ||||||||
MIRT226427 | TP53INP1 | tumor protein p53 inducible nuclear protein 1 | 2 | 2 | ||||||||
MIRT227669 | SET | SET nuclear proto-oncogene | 2 | 2 | ||||||||
MIRT320405 | HOXA9 | homeobox A9 | 2 | 2 | ||||||||
MIRT407774 | MRPL35 | mitochondrial ribosomal protein L35 | 2 | 2 | ||||||||
MIRT439228 | ZMIZ1 | zinc finger MIZ-type containing 1 | 1 | 1 | ||||||||
MIRT439312 | VAT1L | vesicle amine transport 1 like | 1 | 1 | ||||||||
MIRT439421 | TMOD1 | tropomodulin 1 | 1 | 1 | ||||||||
MIRT439446 | TMEM104 | transmembrane protein 104 | 1 | 1 | ||||||||
MIRT439524 | STIM2 | stromal interaction molecule 2 | 1 | 1 | ||||||||
MIRT439612 | SLC29A1 | solute carrier family 29 member 1 (Augustine blood group) | 1 | 1 | ||||||||
MIRT439997 | PFKFB2 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 | 1 | 1 | ||||||||
MIRT440017 | PCSK1 | proprotein convertase subtilisin/kexin type 1 | 1 | 1 | ||||||||
MIRT440131 | NCOA4 | nuclear receptor coactivator 4 | 1 | 1 | ||||||||
MIRT440311 | LRRC1 | leucine rich repeat containing 1 | 1 | 1 | ||||||||
MIRT440475 | IAPP | islet amyloid polypeptide | 1 | 1 | ||||||||
MIRT440511 | HERC2 | HECT and RLD domain containing E3 ubiquitin protein ligase 2 | 1 | 1 | ||||||||
MIRT440617 | FOXA2 | forkhead box A2 | 1 | 1 | ||||||||
MIRT440666 | FBXL16 | F-box and leucine rich repeat protein 16 | 1 | 1 | ||||||||
MIRT440705 | ERO1LB | endoplasmic reticulum oxidoreductase 1 beta | 1 | 1 | ||||||||
MIRT441007 | CAPZA2 | capping actin protein of muscle Z-line alpha subunit 2 | 1 | 1 | ||||||||
MIRT441018 | CAND1 | cullin associated and neddylation dissociated 1 | 1 | 1 | ||||||||
MIRT441062 | C1orf43 | chromosome 1 open reading frame 43 | 1 | 1 | ||||||||
MIRT441209 | ARCN1 | archain 1 | 1 | 1 | ||||||||
MIRT449461 | HAT1 | histone acetyltransferase 1 | 2 | 2 | ||||||||
MIRT467104 | SRI | sorcin | 2 | 2 | ||||||||
MIRT468060 | SHOC2 | SHOC2, leucine rich repeat scaffold protein | 2 | 10 | ||||||||
MIRT468476 | SESN3 | sestrin 3 | 2 | 4 | ||||||||
MIRT473533 | MAX | MYC associated factor X | 2 | 2 | ||||||||
MIRT473852 | MAP2K4 | mitogen-activated protein kinase kinase 4 | 2 | 2 | ||||||||
MIRT474711 | KIF13A | kinesin family member 13A | 2 | 6 | ||||||||
MIRT481665 | ARAP2 | ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 | 2 | 2 | ||||||||
MIRT485120 | SF3B3 | splicing factor 3b subunit 3 | 2 | 2 | ||||||||
MIRT493055 | MTFR1 | mitochondrial fission regulator 1 | 2 | 2 | ||||||||
MIRT504258 | C1orf147 | chromosome 1 open reading frame 147 | 2 | 4 | ||||||||
MIRT504361 | ARID1B | AT-rich interaction domain 1B | 2 | 4 | ||||||||
MIRT505748 | SENP1 | SUMO1/sentrin specific peptidase 1 | 2 | 8 | ||||||||
MIRT506298 | PCMTD1 | protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 | 2 | 6 | ||||||||
MIRT508442 | ZNF608 | zinc finger protein 608 | 2 | 4 | ||||||||
MIRT512782 | COL4A3BP | collagen type IV alpha 3 binding protein | 2 | 2 | ||||||||
MIRT520447 | TSPAN2 | tetraspanin 2 | 2 | 4 | ||||||||
MIRT522133 | NRBF2 | nuclear receptor binding factor 2 | 2 | 6 | ||||||||
MIRT522395 | MYADM | myeloid associated differentiation marker | 2 | 4 | ||||||||
MIRT523397 | GRIK3 | glutamate ionotropic receptor kainate type subunit 3 | 2 | 4 | ||||||||
MIRT523938 | E2F8 | E2F transcription factor 8 | 2 | 4 | ||||||||
MIRT524349 | CREB1 | cAMP responsive element binding protein 1 | 2 | 2 | ||||||||
MIRT524711 | BRMS1L | breast cancer metastasis-suppressor 1 like | 2 | 4 | ||||||||
MIRT525134 | ZNF256 | zinc finger protein 256 | 2 | 2 | ||||||||
MIRT525710 | DCAF12L2 | DDB1 and CUL4 associated factor 12 like 2 | 2 | 2 | ||||||||
MIRT531264 | PPIL3 | peptidylprolyl isomerase like 3 | 2 | 2 | ||||||||
MIRT538844 | BTG1 | BTG anti-proliferation factor 1 | 2 | 2 | ||||||||
MIRT541366 | CDKN1B | cyclin dependent kinase inhibitor 1B | 2 | 2 | ||||||||
MIRT542093 | KCNK10 | potassium two pore domain channel subfamily K member 10 | 2 | 6 | ||||||||
MIRT543770 | RBM12B | RNA binding motif protein 12B | 2 | 4 | ||||||||
MIRT543940 | NCOA7 | nuclear receptor coactivator 7 | 2 | 2 | ||||||||
MIRT545150 | GABRG1 | gamma-aminobutyric acid type A receptor gamma1 subunit | 2 | 2 | ||||||||
MIRT545842 | ZNF264 | zinc finger protein 264 | 2 | 4 | ||||||||
MIRT548057 | GOLGA7 | golgin A7 | 2 | 2 | ||||||||
MIRT549242 | ATXN1L | ataxin 1 like | 2 | 4 | ||||||||
MIRT551829 | AASDHPPT | aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase | 2 | 2 | ||||||||
MIRT552484 | ZNF136 | zinc finger protein 136 | 2 | 2 | ||||||||
MIRT553663 | TGFBR2 | transforming growth factor beta receptor 2 | 2 | 2 | ||||||||
MIRT554988 | RAB39B | RAB39B, member RAS oncogene family | 2 | 2 | ||||||||
MIRT555760 | PCTP | phosphatidylcholine transfer protein | 2 | 2 | ||||||||
MIRT556923 | IRF2BP2 | interferon regulatory factor 2 binding protein 2 | 2 | 4 | ||||||||
MIRT564991 | WNK1 | WNK lysine deficient protein kinase 1 | 2 | 2 | ||||||||
MIRT566458 | PGGT1B | protein geranylgeranyltransferase type I subunit beta | 2 | 2 | ||||||||
MIRT566538 | PANK3 | pantothenate kinase 3 | 2 | 2 | ||||||||
MIRT567732 | DLX2 | distal-less homeobox 2 | 2 | 2 | ||||||||
MIRT570081 | KANSL1L | KAT8 regulatory NSL complex subunit 1 like | 2 | 2 | ||||||||
MIRT571735 | RNF11 | ring finger protein 11 | 2 | 2 | ||||||||
MIRT573529 | MDM2 | MDM2 proto-oncogene | 2 | 2 | ||||||||
MIRT574459 | RPS16 | ribosomal protein S16 | 2 | 2 | ||||||||
MIRT574992 | Phka1 | phosphorylase kinase alpha 1 | 2 | 3 | ||||||||
MIRT576349 | Pxdn | peroxidasin | 2 | 2 | ||||||||
MIRT610196 | CD99 | CD99 molecule (Xg blood group) | 2 | 4 | ||||||||
MIRT612920 | GPRIN3 | GPRIN family member 3 | 2 | 2 | ||||||||
MIRT615021 | DUSP6 | dual specificity phosphatase 6 | 2 | 2 | ||||||||
MIRT623573 | IRS1 | insulin receptor substrate 1 | 2 | 2 | ||||||||
MIRT624437 | CASD1 | CAS1 domain containing 1 | 2 | 2 | ||||||||
MIRT628714 | ZNF585A | zinc finger protein 585A | 2 | 2 | ||||||||
MIRT639565 | PCK1 | phosphoenolpyruvate carboxykinase 1 | 2 | 4 | ||||||||
MIRT641485 | POLA2 | DNA polymerase alpha 2, accessory subunit | 2 | 2 | ||||||||
MIRT641657 | PAPOLG | poly(A) polymerase gamma | 2 | 2 | ||||||||
MIRT642210 | RUVBL2 | RuvB like AAA ATPase 2 | 2 | 2 | ||||||||
MIRT653010 | STX7 | syntaxin 7 | 2 | 2 | ||||||||
MIRT656130 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT656893 | KIAA2018 | upstream transcription factor family member 3 | 2 | 2 | ||||||||
MIRT660130 | BRPF3 | bromodomain and PHD finger containing 3 | 2 | 2 | ||||||||
MIRT660855 | AFAP1 | actin filament associated protein 1 | 2 | 2 | ||||||||
MIRT676843 | PHKA1 | phosphorylase kinase regulatory subunit alpha 1 | 2 | 3 | ||||||||
MIRT681473 | DIP2A | disco interacting protein 2 homolog A | 2 | 2 | ||||||||
MIRT682253 | RS1 | retinoschisin 1 | 2 | 2 | ||||||||
MIRT694296 | COPB2 | coatomer protein complex subunit beta 2 | 2 | 2 | ||||||||
MIRT694401 | ALDH1A3 | aldehyde dehydrogenase 1 family member A3 | 2 | 2 | ||||||||
MIRT705277 | BACH1 | BTB domain and CNC homolog 1 | 2 | 2 | ||||||||
MIRT720833 | C1orf52 | chromosome 1 open reading frame 52 | 2 | 2 | ||||||||
MIRT735713 | SIRT1 | sirtuin 1 | 2 | 0 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|